# Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer ( EV-309 )

> **NCT07566156** · PHASE3 · RECRUITING · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 390 (estimated)

## Conditions studied

- Urothelial Cancer
- Urinary Bladder Neoplasms

## Interventions

- **DRUG:** Enfortumab vedotin
- **RADIATION:** Conventional Radiotherapy
- **RADIATION:** Hypofractionated Radiotherapy
- **DRUG:** Cisplatin
- **DRUG:** Fluorouracil
- **DRUG:** Mitomycin C
- **DRUG:** Gemcitabine
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT07566156
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-11
- **Primary completion:** 2030-03-31
- **Final completion:** 2032-02-29
- **Target enrollment:** 390 (ESTIMATED)
- **Last updated:** 2026-05-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07566156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07566156, "Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer ( EV-309 )". Retrieved via MORVS 2026-10-10 from https://api.morvs.ai/clinical/NCT07566156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*